Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. Monta Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN™ discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs.
Company Details
- Employees
- 194
- Address
- 321 Harrison Ave,
- Phone
- 917-363-0113
- in****@****atx.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- monterosatx.com
- HQ
- Boston, Massachusetts
Monte Rosa Therapeutics Questions
Monte Rosa Therapeutics's helpline number is 917-363-0113
Monte Rosa Therapeutics's website is monterosatx.com
Monte Rosa Therapeutics's LinkedIn profile is https://www.linkedin.com/company/monte-rosa-therapeutics
Monte Rosa Therapeutics has
194 employees.
View email and phone details for 194
employees at Monte Rosa Therapeutics.
Monte Rosa Therapeutics's industry is
Biotechnology Research
Monte Rosa Therapeutics's top competitors are
Alentis Therapeutics,
Ridgeline Discovery,
Ottimo Pharma,
Crescent Biopharma,
Novartis,
Aerovate Therapeutics, Inc.,
Bright Peak Therapeutics,
Jade Biosciences,
Kivu Bioscience,
Axonis Therapeutics.
Monte Rosa Therapeutics's support email address is info@monterosatx.com
Monte Rosa Therapeutics's categories are Biotechnology Research
